These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 37914422)

  • 1. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
    Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant
    Sun Q; Cheng K; Liao X; Zhao W; Wang C; Wang C; Yan J; Dong L; Wang F; Jiang G; Huang H; Guo Z; Wang G
    J Med Microbiol; 2024 Jul; 73(7):. PubMed ID: 39028256
    [No Abstract]   [Full Text] [Related]  

  • 7. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre.
    Li Z; Liu F; Chen H; Han Y; You Y; Xie Y; Zhao Y; Tan J; Guo X; Cheng Y; Wang Y; Li J; Cheng M; Xia S; Niu X; Wei L; Wang W
    J Glob Antimicrob Resist; 2022 Dec; 31():328-336. PubMed ID: 36210030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.
    Bhanushali A; Atre S; Nair P; Thandaseery GA; Shah S; Kuruwa S; Zade A; Nikam C; Gomare M; Chatterjee A
    Microbiol Spectr; 2024 May; 12(5):e0277023. PubMed ID: 38597637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review.
    Pang Y; Lu J; Huo F; Ma Y; Zhao L; Li Y; Liang Q; Chu N; Gao M; Huang H
    J Infect; 2017 Nov; 75(5):433-440. PubMed ID: 28804028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.
    An Q; Lin R; Yang Q; Wang C; Wang D
    J Glob Antimicrob Resist; 2023 Sep; 34():214-226. PubMed ID: 37172764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
    Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.
    Chand AB; Basnet A; Maharjan B; Rai G; Joshi YP; Bhatt LR; Sen B; Rai SK
    PLoS One; 2024; 19(5):e0301210. PubMed ID: 38709710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
    Ahmed I; Jabeen K; Inayat R; Hasan R
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2522-5. PubMed ID: 23507286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.
    Wu SH; Xiao YX; Hsiao HC; Jou R
    Microbiol Spectr; 2022 Dec; 10(6):e0260522. PubMed ID: 36255328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study.
    Pan Y; Yu Y; Yi Y; Dou X; Lu J; Zhou L
    BMC Infect Dis; 2023 Mar; 23(1):162. PubMed ID: 36922787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.